Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials. Zhu Y, Gao Z, Feng X, Hu Y, et al. Antiviral Res 2025;237:106154.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhu Y, Gao Z, Feng X, Hu Y, et al. Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials. Antiviral Res 2025;237:106154.
PMID: 40158858